357.27

3.45% 11.90

Charles River Laboratories International Inc (CRL)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$345.37

Offen:

$347.59

24-Stunden-Volumen:

1.18M

Relative Volume:

0.94

Marktkapitalisierung:

$17.06B

Einnahmen:

$4.03B

Nettoeinkommen (Verlust:

$-182.84M

KGV:

-95.01

EPS:

-3.7603

Netto-Cashflow:

$391.29M

1W Leistung:

+13.26%

1M Leistung:

+22.00%

6M Leistung:

+108.65%

1J Leistung:

+82.95%

1-Tages-Spanne:

$0.00

1-Wochen-Bereich:

$313.83

$357.77

52-Wochen-Spanne:

$146.19

$357.77

Charles River Laboratories International Inc Stock (CRL) Company Profile

Firmenname

Charles River Laboratories International Inc

Sektor

Healthcare (1053)

Branche

Diagnostics & Research (44)

Telefon

781-222-6000

Adresse

251 BALLARDVALE ST, WILMINGTON, MA

Mitarbeiter

19,700

Twitter

@criverlabs

Nächster Verdiensttermin

2026-11-04

Neueste SEC-Einreichungen

CRL's Discussions on Twitter

Compare CRL vs TMO, DHR, NTRA, A, IQV

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
CRL Charles River Laboratories International Inc	357.27	17.06B	4.03B	-182.84M	391.29M	-3.7603
TMO Thermo Fisher Scientific Inc	684.89	253.24B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	232.97	163.77B	24.78B	3.68B	5.29B	5.1743
NTRA Natera Inc	404.90	58.36B	2.50B	-226.32M	71.51M	-1.6412
A Agilent Technologies Inc	175.96	49.61B	7.23B	1.41B	1.09B	4.979
IQV Iqvia Holdings Inc	273.60	45.03B	16.63B	1.39B	2.12B	8.0674

Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-09-30	Fortgesetzt	UBS	Buy
2026-08-06	Hochstufung	JP Morgan	Neutral → Overweight
2026-07-20	Herabstufung	CLSA	Outperform → Hold
2026-06-17	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2026-05-29	Hochstufung	CLSA	Hold → Outperform
2026-04-14	Eingeleitet	RBC Capital Mkts	Outperform
2025-12-15	Hochstufung	BofA Securities	Neutral → Buy
2025-11-17	Hochstufung	Argus	Hold → Buy
2025-11-06	Hochstufung	Robert W. Baird	Neutral → Outperform
2025-10-06	Hochstufung	William Blair	Mkt Perform → Outperform
2025-10-02	Hochstufung	Barclays	Equal Weight → Overweight
2025-09-09	Hochstufung	Jefferies	Hold → Buy
2025-07-09	Hochstufung	Citigroup	Neutral → Buy
2025-05-23	Hochstufung	Redburn Atlantic	Neutral → Buy
2025-05-14	Hochstufung	TD Cowen	Hold → Buy
2025-05-08	Hochstufung	Evercore ISI	In-line → Outperform
2025-03-21	Herabstufung	Goldman	Buy → Neutral
2025-03-04	Hochstufung	Citigroup	Sell → Neutral
2025-03-03	Hochstufung	Redburn Atlantic	Sell → Neutral
2025-01-22	Herabstufung	William Blair	Outperform → Mkt Perform
2025-01-17	Herabstufung	UBS	Buy → Neutral
2024-11-18	Herabstufung	CLSA	Hold → Underperform
2024-11-07	Hochstufung	CLSA	Underperform → Hold
2024-10-23	Eingeleitet	CLSA	Underperform
2024-10-14	Eingeleitet	Redburn Atlantic	Sell
2024-10-07	Herabstufung	Evercore ISI	Outperform → In-line
2024-10-02	Herabstufung	BofA Securities	Buy → Neutral
2024-10-01	Herabstufung	Citigroup	Neutral → Sell
2024-08-08	Herabstufung	JP Morgan	Overweight → Neutral
2024-08-08	Herabstufung	Robert W. Baird	Outperform → Neutral
2024-06-28	Herabstufung	Argus	Buy → Hold
2024-06-07	Eingeleitet	Mizuho	Neutral
2024-06-06	Eingeleitet	Goldman	Buy
2024-02-15	Herabstufung	Guggenheim	Buy → Neutral
2023-09-13	Eingeleitet	TD Cowen	Market Perform
2023-07-10	Herabstufung	Citigroup	Buy → Neutral
2023-02-23	Hochstufung	Guggenheim	Neutral → Buy
2023-01-12	Herabstufung	Jefferies	Buy → Hold
2022-09-30	Hochstufung	Jefferies	Hold → Buy
2022-08-25	Eingeleitet	Credit Suisse	Outperform
2022-08-04	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2022-05-24	Eingeleitet	Guggenheim	Neutral
2022-04-25	Herabstufung	Jefferies	Buy → Hold
2022-04-07	Eingeleitet	Stephens	Overweight
2022-02-17	Bestätigt	BofA Securities	Buy
2022-02-17	Hochstufung	Citigroup	Neutral → Buy
2022-02-17	Bestätigt	Deutsche Bank	Buy
2022-02-17	Bestätigt	Morgan Stanley	Overweight
2022-02-17	Bestätigt	UBS	Buy
2021-08-05	Fortgesetzt	Credit Suisse	Neutral
2020-12-16	Herabstufung	Citigroup	Buy → Neutral
2020-09-10	Hochstufung	Jefferies	Hold → Buy
2020-07-01	Hochstufung	BofA Securities	Neutral → Buy
2020-05-13	Hochstufung	UBS	Neutral → Buy
2020-04-21	Herabstufung	Jefferies	Buy → Hold
2020-03-27	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2020-03-02	Eingeleitet	Deutsche Bank	Buy
2020-02-18	Hochstufung	Wolfe Research	Peer Perform → Outperform
2020-01-10	Hochstufung	Goldman	Neutral → Buy
2020-01-08	Eingeleitet	Wells Fargo	Overweight
2020-01-07	Eingeleitet	Citigroup	Buy
2019-10-18	Herabstufung	BofA/Merrill	Buy → Neutral
2019-06-10	Eingeleitet	SVB Leerink	Outperform
2019-04-30	Fortgesetzt	Evercore ISI	Outperform
2018-12-14	Eingeleitet	Deutsche Bank	Buy
2018-10-09	Eingeleitet	UBS	Neutral
2018-08-23	Hochstufung	Raymond James	Mkt Perform → Outperform
2018-07-17	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2018-06-15	Hochstufung	KeyBanc Capital Mkts	Sector Weight → Overweight
2018-02-14	Hochstufung	SunTrust	Hold → Buy

Alle ansehen

Charles River Laboratories International Inc Aktie (CRL) Neueste Nachrichten

Oct 26, 2026

Charles River Laboratories’ Q3 2026 Earnings: What to Expect - Yahoo Finance

Oct 26, 2026

Oct 25, 2026

Charles River Laboratories International (CRL) Has Fresh Attention, But What Is Behind It? - Simply Wall Street

Oct 25, 2026

Oct 23, 2026

Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch

Oct 23, 2026

Charles River Laboratories International, Inc. Estimates – NYSE:CRL - TradingView

Oct 23, 2026

Oct 22, 2026

Charles River Laboratories (CRL) Partners with FDA and Labcorp t - GuruFocus

Oct 22, 2026

Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors - MarketWatch

Oct 22, 2026

Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment - Finviz

Oct 22, 2026

Charles River Associates (CRA) to Host Third-Quarter Fiscal 2026 Financial Results Conference Call on November 5 - Yahoo Finance

Oct 22, 2026

Oct 21, 2026

$1000 Invested In Charles River 15 Years Ago Would Be Worth This Much Today - Benzinga

Oct 21, 2026

Charles River (CRL) Stock Charges Higher On Bullish Targets And AI Hype - Timothy Sykes

Oct 21, 2026

Charles River Laboratories International Jumps 7.3% in Broad Rally - AlphaStreet

Oct 21, 2026

Charles River Labs Stock Jumps As Street Hikes Targets - StocksToTrade

Oct 21, 2026

Charles River Laboratories stock hits 52-week high at 333.31 USD - Investing.com

Oct 21, 2026

Charles River Laboratories stock hits 52-week high at 333.31 USD By Investing.com - Investing.com South Africa

Oct 21, 2026

Oct 20, 2026

Is Charles River Laboratories International Inc (CRL) Overvalued After 5.1% Rally? GF Value Says Overvalued - GuruFocus

Oct 20, 2026

Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch

Oct 20, 2026

Dilution adjustment of Charles River Laboratories International, Inc. – XETR:RV6 - TradingView

Oct 20, 2026

Morgan Stanley lifts target for Charles River Laboratories stock to USD 340.00 - ad-hoc-news.de

Oct 20, 2026

AI-Driven Drug Discovery Boosts Charles River Laboratories (CRL) Prospects - GuruFocus

Oct 20, 2026

Citrini Bets on Life Sciences Stocks After Claude AI Drug Study - Bloomberg.com

Oct 20, 2026

Oct 17, 2026

Charles River Laboratories International (CRL) Earnings Beat Puts Fair Value Back In Focus - Simply Wall Street

Oct 17, 2026